Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

PURPOSE: To investigate whether anti–vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line letrozole as treatment of hormone receptor–positive metastatic breast cancer (MBC). PATIENTS AND METHODS: Women with hormone receptor–pos...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Dickler, Maura N., Barry, William T., Cirrincione, Constance T., Ellis, Matthew J., Moynahan, Mary Ellen, Innocenti, Federico, Hurria, Arti, Rugo, Hope S., Lake, Diana E., Hahn, Olwen, Schneider, Bryan P., Tripathy, Debasish, Carey, Lisa A., Winer, Eric P., Hudis, Clifford A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2016
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5012690/
https://ncbi.nlm.nih.gov/pubmed/27138575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.66.1595
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg